The survival and peritoneal metastasis of hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: a systematic review and meta-analysis of randomized controlled trials - PubMed
3 hours ago
- #HIPEC
- #gastric-cancer
- #meta-analysis
- HIPEC reduces peritoneal metastasis in advanced gastric cancer (OR: 0.24; 95% CI: 0.16-0.35).
- HIPEC lowers distant metastasis rates (OR: 0.45; 95% CI: 0.28-0.71).
- HIPEC improves 3-year survival (OR: 1.48; 95% CI: 1.01-2.17) and disease-free survival (OR: 1.92; 95% CI: 1.23-3.00).
- HIPEC does not significantly increase complications or adverse events.
- Meta-analysis included 9 RCTs with 1,021 patients.